Trial results for a feasibility study on the VERAFEYE System, relevant for conditions including Atrial Fibrillation, were posted on 2026-02-10, indicating physician feedback on the system was consistently high, reaching 100% in multiple measured aspects.
Background
Atrial Fibrillation (AFib) is a common type of irregular heartbeat that can lead to serious complications like stroke. Current treatments often involve catheter ablation or left atrial appendage closure procedures to restore normal heart rhythm or reduce stroke risk. Technologies that enhance the precision and effectiveness of these procedures are continuously being developed. The VERAFEYE System is designed to support such interventions, and this feasibility study aimed to gather initial performance data to guide its further development and refinement.
Trial design
This completed feasibility study, identified as Phase NA, enrolled 18 participants. The study included subjects undergoing standard of care ablation or closure procedures for conditions such as Atrial Septal Defect, Atrial Fibrillation, Atrial Arrhythmia, and Left Atrial Appendage Closure. The objective was to evaluate the performance of the VERAFEYE System during these procedures. The study was not designed to collect data for product approval and, as such, did not have a safety or efficacy endpoint; its purpose was to guide system development and refinement.
Key results
The study's key results focused on physician feedback regarding the VERAFEYE System within the Catheter-ablation Arm. The feedback, measured as the percentage of participants, showed consistently high responses across various aspects:
- Physician feedback on the VERAFEYE System was 100% in multiple instances.
- Other measures of physician feedback on the system were 94.1%.
- The lowest reported physician feedback on the system was 88.2%.
- Additional feedback measures also reached 100%.
What this means
These results indicate strong positive physician feedback on the VERAFEYE System during its evaluation in procedures for conditions like Atrial Fibrillation. While this feasibility study was not designed for product approval or to establish safety and efficacy, the high percentages of positive feedback, ranging from 88.2% to 100%, suggest that the system performed well from a user perspective. This positive initial feedback is crucial for guiding the ongoing development and refinement of the VERAFEYE System, potentially leading to future advancements in tools used for catheter ablation and closure procedures.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05931835, titled "Feasibility Study on the VERAFEYE System", were posted on 2026-02-10 on clinicaltrials.gov.